Targets › OX40
1 program from 1 company in 1 trial: 1 Phase 2; Immunology; next expected readout Jul 2027.
Open in Phaseline: the race on OX40, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Eli Lilly | Eltrekibart OX40 agonist | OX40 | Phase 2 | Ulcerative Colitis | Jul 2027 |
Ulcerative Colitis (1)
antibody (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.